Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Leases: 2020-2025

Historic Current Leases for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $837,286.

  • SAB Biotherapeutics' Current Leases rose 117.54% to $837,286 in Q3 2025 from the same period last year, while for Sep 2025 it was $837,286, marking a year-over-year increase of 117.54%. This contributed to the annual value of $393,430 for FY2024, which is 41.27% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Current Leases is $837,286, which was up 2.73% from $815,064 recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Current Leases high stood at $1.2 million for Q3 2022, and its period low was $384,892 during Q3 2024.
  • Over the past 3 years, SAB Biotherapeutics' median Current Leases value was $542,841 (recorded in 2024), while the average stood at $589,844.
  • As far as peak fluctuations go, SAB Biotherapeutics' Current Leases tumbled by 57.04% in 2022, and later skyrocketed by 117.54% in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Current Leases stood at $1.1 million in 2021, then crashed by 57.04% to $490,794 in 2022, then spiked by 36.50% to $669,946 in 2023, then crashed by 41.27% to $393,430 in 2024, then surged by 117.54% to $837,286 in 2025.
  • Its last three reported values are $837,286 in Q3 2025, $815,064 for Q2 2025, and $793,360 during Q1 2025.